Navigation Links
CRF announces featured clinical trials to be presented at TCT 2010
Date:8/12/2010

NEW YORK, NY August 12, 2010 The Cardiovascular Research Foundation has announced that in addition to the previously announced late breaking clinical trials and first reports, a series of additional featured trials will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 scientific symposium. These trials will focus on a wide range of significant topics in interventional cardiovascular medicine. TCT 2010 will take place September 21 25 in Washington, DC.

Data from these trials are expected to influence the practice of interventional cardiovascular medicine and have an immediate impact on guidelines and patient care. These featured trials will be highlighted during sessions throughout TCT.

TUESDAY, SEPTEMBER 21, 6:00 PM 7:45 PM

  • SYNTAX Left Main: Three-Year Outcomes from a Prospective Randomized Trial of Paclitaxel-Eluting Stents Compared to Bypass Graft Surgery in Patients with Left Main Coronary Artery Disease
  • SYNTAX 3VD: Three-Year Outcomes from a Prospective Randomized Trial of Paclitaxel-Eluting Stents Compared to Bypass Graft Surgery in Patients with Triple Vessel Coronary Artery Disease
  • EXECUTIVE: A Prospective Randomized Trial of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents in Patients with Multivessel Coronary Artery Disease
  • DECLARE-LONG II: A Prospective Randomized Trial of Triple vs. Dual Antiplatelet Therapy to Reduce Restenosis in Long Coronary Lesions Treated with Zotarolimus-Eluting Stents
  • DK-CRUSH-II: A Prospective Randomized Trial of Double Kissing Crush Stenting Compared to Provisional Stenting for Treatment of True Coronary Bifurcation Lesions
  • TRIAS High Risk: A Prospective Randomized Trial of Endothelial Progenitor Cell Capturing Stents Compared to Other Drug-Eluting Stents in Patients with Complex Coronary Artery Disease
  • ROMA: A Prospective Randomized Trial of Rosuvastatin Pretreatment Prior to Percutaneous Coronary Intervention
  • COMPARE-AMI: Two-Year Outcomes from a Prospective, Randomized Trial of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents in Patients with STEMI

WEDNESDAY, SEPTEMBER 22, 6:00 PM 8:00 PM

  • LEADERS: Three-Year Follow-up from a Prospective Randomized Trial of Biolimus A9-Eluting Stents and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease
  • ESSENCE-DIABETES: A Prospective Randomized Trial of Everolimus-Eluting Stents and Sirolimus-Eluting Stents in Patients with Diabetes Mellitus and Coronary Artery Disease
  • ZEST: Two-Year Outcomes from a Prospective, Randomized Trial of Sirolimus-Eluting Stents, Paclitaxel-Eluting Stents and Zotarolimus-Eluting Stents in Patients with Coronary Artery Disease
  • APPOSITION II: A Prospective Randomized Trial of Self-Expanding vs. Balloon Expandable Stents in Patients with Acute Myocardial Infarction
  • CLOVIS-2: A Prospective, Randomized, Nested Case-Control Crossover Study of a High vs. Low Clopidogrel Loading Dose in Clopidogrel Resistant Patients With and Without the CYP2C19*2 Loss-of-Function Allele
  • PRO-GR: A Prospective, Randomized, Crossover Study of Maintenance High-Dose Clopidogrel vs. Prasugrel in Patients With and Without the CYP2C19*2 Loss-of-Function Allele
  • SOURCE TAVI Cohort 2: A Prospective Observational Study of More Than 2,300 Lower Risk and "Valve-in-Valve" Patients Undergoing Transcatheter Aortic Valve Implantation
  • PFO Closure: A Prospective Nonrandomized Propensity-Adjusted Study of PFO Closure Compared to Medical Therapy in Patients with Stroke Presumably Related to PFO

FRIDAY, SEPTEMBER 24, 6:00 PM 8:00 PM

  • LANCELOT CAD: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of a Reversible PAR-1 Thrombin Receptor Antagonist in Patients with Coronary Artery Disease
  • MYTHOS: A Prospective Randomized Trial of Furosemide-Induced High-Volume Diuresis with Matched Hydration Using a Dedicated Device to Prevent Contrast Nephropathy
  • ODS-CAS: A Prospective Randomized Trial of Iso-Osmolar Contrast Compared to Low-Osmolar Contrast to Prevent Contrast Nephropathy in Patients Undergoing Carotid Artery Stenting
  • STEM CELL MOBILIZATION: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Granulocyte Colony Stimulating Factor After Acute Myocardial Infarction in Patients with Low Left Ventricular Ejection Fraction
  • PREVENT-ICARUS: A Prospective, Randomized, Double-Blind Trial of Intracoronary Adenosine to Prevent Periprocedural Myonecrosis in Patients Undergoing Elective Coronary Angioplasty
  • CRYSTAL AMI: A Prospective Randomized Trial of Intracoronary Site-Specific Abciximab Compared to Intravenous Abciximab in Patients with Acute Myocardial Infarction Undergoing Primary Angioplasty
  • PEPCAD-CTO: A Prospective Nonrandomized Study of Paclitaxel-Eluting Balloons After Bare Metal Stent Placement in Successfully Recanalized Chronic Total Coronary Occlusions

Media may apply for registration by clicking on: http://www.tctconference.com/press/press-registration-form.html

Details on required press credentials can be found at: http://www.tctconference.com/press/press-credentials-a-guidelines.html

To view the program update, visit: http://www.tctconference.com/pdf/2010program-update.pdf

Receive updates on Twitter: http://twitter.com/TCTConference

View related video content on YouTube: http://www.youtube.com/user/TCTConference


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2009 Financial Results
2. Connecture, Inc. Announces Partnership with MedicareCRM
3. Chiquita Announces Support for School Salad Bar Campaign
4. Team Health Holdings, Inc., Announces Fourth Quarter and Fiscal 2009 Financial Results
5. MDS Announces Agreements to Divest MDS Pharma Services Early Stage Business
6. MyDietShopz.com Announces Biggest Losers Contest - Share Your Story To Inspire Others
7. Rocketboy Media Wins Award for Masonic Lodge Web Site; Announces Signing of Several New Clients
8. Emergency Nurses Association Announces Corporate Sponsors for Leadership Conference
9. Whitemark Homes Inc. Announces Change of Auditors and Additional Corporate Information
10. Sunquest Announces Major Software Updates and Enhancements
11. Data Strategy Announces SurePath Services Offering for EMC Avamar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... February 13, 2016 , ... In the early or “honeymoon” stage ... to perfection, go out of their way to be romantic, and may exaggerate a ... look at any online dating profile. , A recent study from Queendom.com ...
(Date:2/12/2016)... Opelousas, LA (PRWEB) , ... February 12, 2016 , ... ... of St. Landry and Evangeline Parishes. The purpose of these scholarships is to ... to encourage those individuals to seek employment within these two parishes. , “We ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fixed Dose Combination Drug Development: ... EST, http://www.fdanews.com/fixeddosecombination , Fixed dose combination products are ... attention from all stakeholders in the development of new chemical entities. , However, ...
(Date:2/12/2016)... ... 2016 , ... T.E.N., a technology and information security executive ... Awards 2016. Finalists and winners of the ISE® Awards for both Executive and ... Gala on March 15, 2016 at the Westin Peachtree Plaza, Atlanta. , ...
(Date:2/12/2016)... ... 12, 2016 , ... Fisher House Foundation Chairman and CEO Kenneth Fisher joined ... Support Alliance president Scott Bensing, and Peggy Kearns Director, VA Southern Nevada Healthcare System ... This will be the first Fisher House in Nevada, and will provide free ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... , Feb. 11, 2016 Potrero Medical, Inc., the ... to announce the appointment of George M. Rapier, III ... San Antonio, TX , WellMed is one of the ... patients and HMO members in Texas ... 1990 out of his own internal medicine practice, he has ...
(Date:2/11/2016)... -- MiMedx Group, Inc. (NASDAQ: MDXG ), the leading ... birth tissues, human skin and bone, and patent-protected processes ... and therapies, announced today that it will present at ... New York , NY.  Parker H. ... , Chief Financial Officer and Chris Cashman , ...
(Date:2/11/2016)...  AfterPill.com is reporting that this week,s Centers for ... women who are at risk of unintended pregnancy impacts ... raises the risks of unprotected sex in particular.  ... to the Guttmacher Institute, there are 43 million women ... who have sex without the intention of becoming pregnant.  ...
Breaking Medicine Technology: